Covaxin safe for children aged 2-18 years, says Bharat Biotech
Monday, June 27, 2022
  • Circulation
  • Advertise
  • About Us
  • Contact Us
Organiser
  • ‌
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Sports
  • Business
  • More
    • RSS in News
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
SUBSCRIBE
No Result
View All Result
Organiser
  • ‌
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Sports
  • Business
  • More
    • RSS in News
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
No Result
View All Result
Organiser
No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Opinion
  • Analysis
  • Culture
  • Defence
  • RSS in News
  • Subscribe
Home Bharat

Covaxin safe for children aged 2-18 years, says Bharat Biotech

Bharat Biotech has a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required.

WEB DESK by WEB DESK
Jun 17, 2022, 04:33 pm IST
in Bharat
COVAXIN

COVAXIN

Share on FacebookShare on TwitterTelegramEmail

Hyderabad (Telangana): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press release.

The study has been accepted and published in Lancet Infectious Diseases, a peer-reviewed high-impact factor journal, added the statement.

Bharat Biotech had conducted phase II/III, open-label, and multicentre studies to evaluate the safety, reactogenicity, and immunogenicity of COVAXIN in healthy children and adolescents in the 2-18 years of age group. The clinical trial conducted in the pediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) in October 2021 and received a nod for emergency use in children aged 6-18years.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Safety of the vaccine is critical for children and we are glad to share that COVAXIN has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children, for primary immunization and booster doses, and making COVAXIN a universal vaccine. It has proven to be a highly safe vaccine based on data from more than 50 million doses administered to children in India. Vaccines are a great preventive tool; the power of vaccines can only be harnessed if used prophylactically.”

In the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within 1 day. Pain at the injection site was the most commonly reported adverse event.

COVAXIN is formulated uniquely such that the same dosage can be administered to adults and children alike, for primary and booster doses, making it truly a universal vaccine. COVAXIN is a ready-to-use liquid vaccine, stored at 2-8°C, with 12 months shelf life and a multi-dose vial policy.

The whole virion inactivated vaccines have proven to be safe, and tolerable with a safety track record of several decades. Several paediatric vaccines manufactured using this platform technology are utilized in routine immunization for primary immunization and booster doses. Several flu vaccines also utilize this manufacturing platform technology, which is safe and effective for repeated annual immunization doses and boosters.

Bharat Biotech has a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required. Bharat Biotech has established COVAXIN manufacturing to reach an annualised capacity of 1 billion doses by the end of 2021. (ANI)

 

Topics: IndiaCOVAXINBharat BiotechCOVID19
ShareTweetSendShareSend
Previous News

China Blocks India’s Move To List Pakistan-Based Abdul Rehman Makki As Global Terrorist

Next News

Jammu And Kashmir: 3 Hizb-ul-Mujahideen terrorists including school teacher Rajni Bala’s murderers neutralized

Related News

‘Congress snatched Constitutional rights of every Indian overnight for power’: Amit Shah on 47 years of Emergency

‘Congress snatched Constitutional rights of every Indian overnight for power’: Amit Shah on 47 years of Emergency

At UNSC briefing on Afghanistan India expresses grief over tragic earthquake, vows to provide support

At UNSC briefing on Afghanistan India expresses grief over tragic earthquake, vows to provide support

China’s appalling behaviour in South China Sea akin to what India saw at LAC: Australian Defence Minister

China’s appalling behaviour in South China Sea akin to what India saw at LAC: Australian Defence Minister

India reports 12,249 new COVID cases, 13 deaths

ACB to begin probe into PWD’s 1256 crore scam by Kejriwal Govt, while building 7 Hospitals during COVID-19 second wave

ACB to begin probe into PWD’s 1256 crore scam by Kejriwal Govt, while building 7 Hospitals during COVID-19 second wave

Presidential Election: Gopalkrishna Gandhi Declines Opposition’s Offer To Be Presidential Candidate

Presidential Election: Gopalkrishna Gandhi Declines Opposition’s Offer To Be Presidential Candidate

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

UP by-polls: Akhilesh Yadav’s bastion falls, BJP unfurls lotus in Azam Khan stronghold Rampur

UP by-polls: Akhilesh Yadav’s bastion falls, BJP unfurls lotus in Azam Khan stronghold Rampur

Mamata Banerjee’s Tripura dream ended; TMC gets merely 2.86 per cent of votes in by-polls

Mamata Banerjee’s Tripura dream ended; TMC gets merely 2.86 per cent of votes in by-polls

Gujarat anti-terrorist squad team arrests Teesta Setalvad in Mumbai

Arrested following SC verdict, Teesta earlier faced a funds embezzlement case

Punjab Bypolls: Khalistani sympathizer Simranjit Singh Mann wins Sangrur

Punjab Bypolls: Khalistani sympathizer Simranjit Singh Mann wins Sangrur

Teesta Setalvad: An NGO racketeer who ran smear campaign against Narendra Modi

Teesta Setalvad: An NGO racketeer who ran smear campaign against Narendra Modi

Gujarat Police arrests Teesta Setalvad; says ‘not cooperating’, seeks 14-day custody

Gujarat Police arrests Teesta Setalvad; says ‘not cooperating’, seeks 14-day custody

People of India defeated dictatorial mindset in democratic way: PM Modi invokes 1975 Emergency in Mann Ki Baat

People of India defeated dictatorial mindset in democratic way: PM Modi invokes 1975 Emergency in Mann Ki Baat

PM Modi lauds Olympic medalist Neeraj Chopra for his recent performances in javelin throw

PM Modi lauds Olympic medalist Neeraj Chopra for his recent performances in javelin throw

How Communist rule in West Bengal ruined the state?

How Communist rule in West Bengal ruined the state?

Roofless Sabha mandapa of Anandeshwar temple

Roofless Sabha mandapa of Anandeshwar temple

  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping Policy

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Culture
  • Sports
  • Business
  • RSS in News
  • Special Report
  • Sci & Tech
  • Entertainment
  • Education
  • Books
  • Interviews
  • Travel
  • Health
  • Obituary
  • Subscribe
  • Advertise
  • Circulation
  • About Us
  • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Refund and Cancellation

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies